174 related articles for article (PubMed ID: 24751454)
1. Decreased sputum caveolin-1 is associated with systemic sclerosis related lung disease.
Yilmaz N; Olgun S; Ahiskali R; Karakurt S; Yavuz S
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Apr; 31(1):55-61. PubMed ID: 24751454
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
3. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
4. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
5. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
[TBL] [Abstract][Full Text] [Related]
6. Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis.
Sakamoto N; Kakugawa T; Hara A; Nakashima S; Yura H; Harada T; Ishimoto H; Yatera K; Kuwatsuka Y; Hara T; Ichinose K; Obase Y; Ishimatsu Y; Kohno S; Mukae H
Respir Res; 2015 Dec; 16():148. PubMed ID: 26654954
[TBL] [Abstract][Full Text] [Related]
7. [Increase of CXCL10 serum level in systemic sclerosis interstitial pneumonia].
Tiev KP; Chatenoud L; Kettaneh A; Tolédano C; Bach JF; Cabane J
Rev Med Interne; 2009 Nov; 30(11):942-6. PubMed ID: 19577826
[TBL] [Abstract][Full Text] [Related]
8. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory profile of induced sputum composition in systemic sclerosis and comparison with healthy volunteers.
Jacquerie P; Henket M; André B; Moermans C; de Seny D; Gester F; Louis R; Malaise M; Guiot J
Sci Rep; 2021 May; 11(1):10679. PubMed ID: 34021175
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate antigen 15.3 as a serum biomarker of interstitial lung disease in systemic sclerosis patients.
Celeste S; Santaniello A; Caronni M; Franchi J; Severino A; Scorza R; Beretta L
Eur J Intern Med; 2013 Oct; 24(7):671-6. PubMed ID: 23697634
[TBL] [Abstract][Full Text] [Related]
11. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
Hant FN; Ludwicka-Bradley A; Wang HJ; Li N; Elashoff R; Tashkin DP; Silver RM;
J Rheumatol; 2009 Apr; 36(4):773-80. PubMed ID: 19286849
[TBL] [Abstract][Full Text] [Related]
12. Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease.
Saigusa R; Asano Y; Nakamura K; Yamashita T; Ichimura Y; Takahashi T; Toyama T; Taniguchi T; Yoshizaki A; Miyazaki M; Tamaki Z; Sato S
Mod Rheumatol; 2017 Jul; 27(4):618-622. PubMed ID: 27538472
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
[TBL] [Abstract][Full Text] [Related]
14. Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis--association with pulmonary involvement.
Dziankowska-Bartkowiak B; Waszczykowska E; Dziankowska-Zaboroszczyk E; de Graft-Johnson JE; Zalewska A; Łuczyńska M; Nowak D
Clin Exp Rheumatol; 2006; 24(5):508-13. PubMed ID: 17181918
[TBL] [Abstract][Full Text] [Related]
15. Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease.
Meier C; Freiburghaus K; Bovet C; Schniering J; Allanore Y; Distler O; Nakas C; Maurer B
Sci Rep; 2020 Dec; 10(1):21912. PubMed ID: 33318574
[TBL] [Abstract][Full Text] [Related]
16. Pleural irregularity, a new ultrasound sign for the study of interstitial lung disease in systemic sclerosis and antisynthetase syndrome.
Pinal-Fernandez I; Pallisa-Nuñez E; Selva-O'Callaghan A; Castella-Fierro E; Simeon-Aznar CP; Fonollosa-Pla V; Vilardell-Tarres M
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S136-41. PubMed ID: 26315813
[TBL] [Abstract][Full Text] [Related]
17. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis.
Meloni F; Caporali R; Marone Bianco A; Paschetto E; Morosini M; Fietta AM; Patrizio V; Bobbio-Pallavicini F; Pozzi E; Montecucco C
Sarcoidosis Vasc Diffuse Lung Dis; 2004 Jun; 21(2):111-8. PubMed ID: 15281432
[TBL] [Abstract][Full Text] [Related]
18. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort.
Hoffmann-Vold AM; Fretheim H; Halse AK; Seip M; Bitter H; Wallenius M; Garen T; Salberg A; Brunborg C; Midtvedt Ø; Lund MB; Aaløkken TM; Molberg Ø
Am J Respir Crit Care Med; 2019 Nov; 200(10):1258-1266. PubMed ID: 31310156
[No Abstract] [Full Text] [Related]
19. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
Numajiri H; Yoshizaki A; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Sumida H; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Sato S
J Dermatol; 2018 Oct; 45(10):1221-1224. PubMed ID: 30051925
[TBL] [Abstract][Full Text] [Related]
20. Serum interleukin-34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease.
Kuzumi A; Yoshizaki A; Toyama S; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Asano Y; Sato S
J Dermatol; 2018 Oct; 45(10):1216-1220. PubMed ID: 30004593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
